Group 1 - China Feihe donated to the Special Fund for the Protection and Utilization of the Site of the Japanese Army's Unit 731, demonstrating its commitment to historical heritage protection [1][3] - The donation aims to support the application of the Unit 731 site for World Cultural Heritage status, showcasing the company's role in social responsibility and historical memory preservation [3] - Founded in 1962, China Feihe is one of the earliest milk powder companies in China, originating from Qiqihar, Heilongjiang [3] Group 2 - The donation serves as a high-standard practical example for social participation in historical heritage protection, emphasizing its historical, public, and educational value [3] - The financial support provided by China Feihe strengthens the foundation for the protection of the Unit 731 site [3] - The act reflects China Feihe's commitment as a national enterprise to uphold the memory of the nation and fulfill its social responsibilities [3]

Core Viewpoint - China Feihe Dairy has been awarded the nomination for the 5th China Quality Award, becoming the only infant formula company to receive this honor, which signifies a significant advancement in the quality management level of China's dairy industry [1][4][6]. Group 1: Award Significance - The China Quality Award is the highest honor in quality management, established by the central government and organized by the State Administration for Market Regulation, aimed at recognizing significant innovations in quality management [4]. - Feihe's nomination is a testament to its long-standing commitment to high-quality development and serves as a benchmark for the dairy industry [1][4]. Group 2: Quality Management Practices - Feihe has maintained a record of zero accidents in safety production for 63 years, emphasizing its core principle that quality should not be compromised [6][12]. - The company has developed a comprehensive quality management system, including 1,322 quality management regulations covering all processes from farming to production [12]. Group 3: Innovation and Research - Feihe has established an integrated industrial chain model that combines agriculture, animal husbandry, and manufacturing, ensuring quality control from source to end product [7][10]. - The company leads national research on breast milk, creating the largest maternal and infant health database in China, which supports the development of infant formula tailored to Chinese babies [10][15]. Group 4: Market Position and Recognition - Feihe has been the top seller in the Chinese infant formula market for six consecutive years and ranks first globally in sales [13][15]. - The brand has achieved a recognition rate of 99% among consumers, solidifying its position as a market leader [13]. Group 5: Future Directions - Feihe aims to continue its commitment to quality and innovation, enhancing its quality management system to lead the high-quality development of the dairy industry [16].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 China Feihe Limited 中國飛鶴有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：6186） 須予披露交易 認購金融產品 認購金融產品 茲 提 述 本 公 司 日 期 為 二 零 二 五 年 一 月 十 五 日、二 零 二 五 年 一 月 二 十 二 日、二 零 二 五 年 二 月 十 一 日、二 零 二 五 年 二 月 十 八 日、二 零 二 五 年 三 月 二 十 四 日、二 零 二 五 年 五 月 八 日、二 零 二 五 年 五 月 十 四 日、二 零 二 五 年 五 月 二 十 日 及 二 零 二 五 年 八 月 四 日 的 公 告，內 容 有 關 本 集 團 認 購 若 干 浦 發 銀 行 的 理 財 及 結 構 性 存 款 金融產品（「認購浦發銀行金融產品」）。 董 事 會 宣 佈， ...

Investment Rating - The investment rating for the company is maintained as "Buy" [8] Core Views - The company experienced a revenue decline of 9.4% year-on-year in the first half of 2025, with total revenue reaching 9.15 billion yuan and a net profit of 1.03 billion yuan, down 46% [1][2] - The decline in revenue is attributed to competitive pressures in the industry, consumer subsidies for childbirth, and inventory reduction efforts [2] - The gross margin decreased to 61.6%, down 6.3 percentage points, primarily due to an increased proportion of sales from raw milk products [3] - The company has a strong commitment to shareholder returns, distributing a mid-term dividend of 1 billion yuan, representing a 100% payout ratio [4] Financial Summary - Revenue projections for 2025-2027 are 19.04 billion, 19.99 billion, and 20.83 billion yuan, with year-on-year changes of -8.2%, +5.0%, and +4.2% respectively [5] - The forecasted net profit for the same period is 2.31 billion, 2.60 billion, and 2.98 billion yuan, with year-on-year changes of -35.4%, +13.0%, and +14.6% respectively [5] - The company’s earnings per share (EPS) for 2025 is projected at 0.25 yuan, with a price-to-earnings (P/E) ratio of 15.71 [7]

| 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06186 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000,000 | USD | 0.000000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000,000 | USD | 0.000000025 | USD | | 50,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 中國飛鶴有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 ...

Core Viewpoint - The company reported a significant decline in revenue and net profit for 1H25, aligning with previous profit warnings, primarily due to inventory reduction and competitive pressures in the market [1][2]. Revenue Performance - The company's revenue for 1H25 was 9.15 billion yuan, a year-on-year decrease of 9.4%, while the net profit attributable to shareholders was 1 billion yuan, down 46.7% [1]. - The decline in revenue was attributed to intense industry competition, proactive inventory reduction, and delays in new product launches due to regulatory approvals [1]. - The company's market share decreased by over 1 percentage point during the first half of the year, with all product lines experiencing negative growth [1]. Profitability Analysis - The gross profit margin for 1H25 fell by 6.3 percentage points to 61.6%, influenced by impairment losses on bulk powder and a 1.2 billion yuan sales subsidy that negatively impacted revenue [2]. - The sales expense ratio remained stable, while the management expense ratio increased by 1.1 percentage points due to reduced economies of scale from declining revenue [2]. - Additional negative impacts on net profit included a reduction in government subsidies by 150 million yuan and a 100 million yuan increase in fair value losses related to livestock [2]. Future Outlook - The company anticipates continued pressure on revenue in the second half of the year due to ongoing inventory adjustments, although inventory levels have reached historical lows [3]. - A potential improvement in revenue performance is expected starting in September, with a more noticeable recovery in Q4, despite an overall projected double-digit decline for the year [3]. - The company is actively expanding its overseas presence and full lifecycle health business, with current international operations covering North America, the Middle East, and Southeast Asia [3]. Shareholder Returns - The company has announced a minimum dividend of 2 billion yuan for the year, corresponding to a payout ratio of over 90% and a dividend yield of 6.7%, along with a share buyback plan of around 1 billion yuan [3]. Earnings Forecast and Valuation - Due to inventory adjustments and impairment losses, the earnings forecasts for 2025 and 2026 have been reduced by 24% and 17%, respectively, to 2.19 billion yuan and 3.05 billion yuan [3]. - The target price has been lowered by 11.67% to 5.3 HKD, reflecting a price-to-earnings ratio of 20 and 14 times for 2025 and 2026, respectively, with a potential upside of 21% [3].

Core Insights - The company reported a revenue of 9.151 billion yuan for H1 2025, a decrease of 9.36% year-on-year, and a net profit attributable to shareholders of 1 billion yuan, down 46.66% [1] - The company plans to distribute an interim dividend of 0.1209 HKD per share [1] Revenue Performance - The company actively reduced inventory, leading to a decline in infant formula revenue, with dairy products and nutritional supplements revenue at 9.143 billion yuan and raw milk revenue at 0.08 billion yuan, down 9.08% and 79.82% respectively [1] - Revenue from mainland China, the US, and Canada was 9.041 billion yuan, 0.0091 billion yuan, and 0.0018 billion yuan, reflecting year-on-year changes of -9.47%, +11.94%, and -30.69% respectively [1] - Online channel revenue share increased, with offline channel revenue accounting for 71.9% in H1 2025, down from 76.8% in H1 2024 [1] Profitability Analysis - The company's gross margin was 61.58%, a decrease of 6.30 percentage points year-on-year, primarily due to increased costs of raw milk powder [1] - The net profit margin attributable to shareholders was 10.93%, down 7.64 percentage points year-on-year, influenced by declining gross margin, reduced government subsidies and interest income, increased administrative expenses, and changes in the fair value of biological assets [1] - Other income and gains decreased by 37.4% to 540 million yuan, mainly due to reduced government subsidies and interest income, while administrative expenses increased by 4.7% to 774 million yuan, driven by higher employee compensation [1] Investment Outlook - The company is projected to achieve net profits attributable to shareholders of 3.007 billion yuan, 3.472 billion yuan, and 3.818 billion yuan for 2025, 2026, and 2027, reflecting year-on-year growth rates of -15.78%, 15.48%, and 9.96% respectively [1] - The corresponding price-to-earnings ratios for August 28 are expected to be 12, 10, and 9 times, with a market capitalization of 39.5 billion HKD, maintaining a "buy" rating [1]

Core Viewpoint - The company reported a decline in revenue and profit for the first half of 2025, attributed to intensified competition and proactive inventory reduction measures [1] Financial Performance - The company achieved a main revenue of 9.151 billion yuan in H1 2025, a year-on-year decrease of 9.36% [1] - The net profit attributable to shareholders was 1 billion yuan, down 46.66% year-on-year [1] - The gross profit margin was 61.58%, a decrease of 6.3 percentage points year-on-year [1] - The net profit margin was 10.93%, down 7.64 percentage points year-on-year [1] Revenue Breakdown - Revenue from ultra-high-end, high-end, ordinary, and adult milk powder was 6.19 billion, 1.69 billion, 330 million, and 290 million yuan respectively, with year-on-year changes of -13%, -14%, +3%, and -4% [1] - Online sales performed better than offline, with offline revenue at 6.58 billion yuan (down 15%) and online revenue at 2.57 billion yuan (up 10%) [1] Cost and Expenses - Selling expense ratio was 34.69%, a slight decrease of 0.33 percentage points year-on-year [1] - Management expense ratio increased to 8.46%, up 1.14 percentage points year-on-year due to reduced economies of scale and increased employee compensation [1] - Other income and gains decreased, primarily due to reduced government subsidies and interest income [1] Market Position and Strategy - The company faced significant operational pressure due to intensified market competition and slow approval of new ultra-high-end products [1] - The market share declined by over 1 percentage point to 18.2% in June 2025 [1] - The company is actively adjusting its operations, with inventory levels reaching healthy targets and plans to launch three customized products in the second half of the year [1] Future Outlook - The company aims to improve its operational performance through product launches and inventory adjustments, with expectations for revenue growth [1] - The target price for 2026 is set at 5.1 HKD, with a recommendation to monitor the performance of new products [2]

Core Viewpoint - The company experienced a decline in revenue and net profit in the first half of 2025, attributed to various market pressures, but maintained its leading market position in the industry [1][2]. Group 1: Financial Performance - In 25H1, the company achieved revenue of 9.15 billion yuan, a year-on-year decrease of 9.4% [1]. - The net profit attributable to shareholders was 1 billion yuan, down 46.7% year-on-year [1]. - The overall gross margin for 25H1 was 61.6%, a decrease of 6.3 percentage points, primarily due to an increase in sales of lower-margin raw materials [2]. - The net profit margin for 25H1 was 11.3%, down 7.7 percentage points year-on-year [2]. - The company plans to invest no less than 1 billion yuan in share buybacks and distribute dividends of at least 2 billion yuan in 2025 [2]. Group 2: Market Position and Strategy - Despite the revenue decline, the company maintained the top market share in the infant formula sector, with an 18.2% market share as of June 2025 [1]. - The company launched a 1.2 billion yuan fertility subsidy plan in response to national policies, with most of the subsidies utilized in the second quarter [3]. - The company is expanding its overseas business, with overseas revenue of approximately 110 million yuan in 25H1, and plans to enter the U.S. market by the end of the year [3]. Group 3: Channel Development - The company operates through over 2,700 offline clients, covering about 70,000 retail points, and has conducted over 380,000 face-to-face activities to enhance consumer engagement [2]. - Online engagement has also been significant, with over 430 million visits to the membership platform and more than 22 million interactions on public accounts [2].

Summary of China Feihe's Conference Call Company Overview - **Company**: China Feihe - **Industry**: Dairy and Nutrition Products Key Points Financial Performance - In the first half of 2025, China Feihe achieved a revenue of **91.5 billion RMB**, a **9.4% decrease** year-on-year, and a net profit of **10.03 billion RMB**, down **46%** year-on-year [2][3][14] - High-end infant formula accounted for **68%** of total revenue, with a gross margin of **62%**, which is a **17.8% decline** compared to the previous year [3][14] - The company expects a revenue guidance of **210 billion RMB** for the full year 2026, with a profit forecast of around **20 billion RMB** [17][22] Research and Development - R&D investment reached **250 million RMB** in the first half of 2025, collaborating with top institutions like Harvard Boston Children's Hospital and Tsinghua University [1][3] - Achievements include a leading technology in milk protein extraction and the first comprehensive database for human milk oligosaccharides (HMO) in China [3][4] Brand Building and Market Promotion - Over **380,000 offline events** were held, and the Xin Mama Club platform had over **430 million visits** and nearly **1.8 million interactions**, maintaining the industry's leading brand presence [1][5] - The company focuses on high-end product launches to meet market demand [5] Supply Chain Management - Implemented a flat channel strategy to enhance supply chain efficiency, achieving a **97%** delivery rate within **10 days** [1][6] - Significant cost reduction efforts in the supply chain have been noted [6] Product Development - Revenue from cheese and children's products reached **36 million RMB**, with the "Love Eating Vegetable Cheese" product ranking first on multiple online platforms [10] - The functional nutrition business generated nearly **50 million RMB**, with a **500% growth** in main products, driving an overall growth of **55%** [11] Market Challenges and Strategies - The company faced a **1% decline** in market share due to inventory reduction measures and a strategic shift towards healthier projects [15][16] - The competitive landscape has intensified, with increased demand for customized products that offer higher margins [16] Future Outlook - The company anticipates improved performance in 2026, with adjusted inventory levels and new customized products set to launch [17][20] - Plans to expand overseas markets, particularly in Southeast Asia and Canada, are underway [13][19] Operational Adjustments - Inventory adjustments have been made, with current levels at their lowest in five to six years, which is expected to enhance profitability [18] - The company is focusing on deep processing capabilities to improve gross margins and profitability in the future [24][25] Shareholder Returns - A commitment to maintain dividends of no less than **2 billion RMB**, although it may differ from the previous year's **2.7 billion RMB** [17][19] Additional Insights - The company has established a cream production line, enhancing its deep processing capabilities for future product offerings [25] - The introduction of a digital assistant, "He Xiaofei," has improved customer engagement with a response rate of **100%** and accuracy over **95%** [9] This summary encapsulates the essential insights from the conference call, highlighting China Feihe's financial performance, strategic initiatives, and future outlook in the dairy and nutrition industry.